New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

Plegridy (peginterferon beta-1a) is a long-acting treatment for RRMS in which interferon beta-1a – the active ingredient in Biogen's Avonex (interferon beta-1a) – is pegylated to make the

Biogen grows in Q2, but Spinraza performance a concern

The performance was thanks largely to its under-pressure multiple sclerosis (MS) franchise, where combined sales of Tecfidera, Avonex, Plegridy and Tysabri totalled $2.2bn.

Celgene hopes for second time lucky for ozanimod FDA filing

The new submission is based on the SUNBEAM study, a phase 3 trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod against weekly Avonex, current standard of ... It also pooled data from RADIANCE part B, another phase 3

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

Teva’s Copaxone, Biogen’s Avonex and Merck Serono’s Rebif have all been accepted for routine use on the NHS after the companies agreed to lower their prices – in addition

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]